NO20065074L - Nye orale formuleringer av ospemifen. - Google Patents

Nye orale formuleringer av ospemifen.

Info

Publication number
NO20065074L
NO20065074L NO20065074A NO20065074A NO20065074L NO 20065074 L NO20065074 L NO 20065074L NO 20065074 A NO20065074 A NO 20065074A NO 20065074 A NO20065074 A NO 20065074A NO 20065074 L NO20065074 L NO 20065074L
Authority
NO
Norway
Prior art keywords
ospemifene
oral formulations
new oral
pharmaceutically acceptable
stereoisomer
Prior art date
Application number
NO20065074A
Other languages
English (en)
Other versions
NO338736B1 (no
Inventor
Veli-Matti Lehtola
Markku Anttila
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of NO20065074L publication Critical patent/NO20065074L/no
Publication of NO338736B1 publication Critical patent/NO338736B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det beskrives en flytende eller halvfast peroral medikamentformulering, omfattende en terapeutisk aktiv forbindelse med formel (I) eller en geometrisk isomer, en stereoisomer, et farmasøytisk akseptabelt salt, en ester av denne eller en metabolitt av denne, i kombinasjon med en farmasøytisk akseptabel bærer.
NO20065074A 2004-05-04 2006-11-03 Nye flytende orale formuleringer av ospemifen NO338736B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56752504P 2004-05-04 2004-05-04
PCT/FI2005/000131 WO2005105052A1 (en) 2004-05-04 2005-03-02 Novel oral formulations of ospemifene

Publications (2)

Publication Number Publication Date
NO20065074L true NO20065074L (no) 2006-11-29
NO338736B1 NO338736B1 (no) 2016-10-17

Family

ID=35241411

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20065074A NO338736B1 (no) 2004-05-04 2006-11-03 Nye flytende orale formuleringer av ospemifen
NO20161206A NO343582B1 (no) 2004-05-04 2016-07-21 Oral medikamentformulering omfattende ospemifen

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20161206A NO343582B1 (no) 2004-05-04 2016-07-21 Oral medikamentformulering omfattende ospemifen

Country Status (19)

Country Link
US (1) USRE47316E1 (no)
EP (2) EP2275098B1 (no)
JP (3) JP5497983B2 (no)
KR (1) KR101278934B1 (no)
CN (1) CN1950071A (no)
AU (2) AU2005237274B2 (no)
BR (1) BRPI0510465B8 (no)
CA (1) CA2565134C (no)
CY (2) CY1113280T1 (no)
DK (2) DK2275098T3 (no)
ES (2) ES2391626T3 (no)
HK (1) HK1151227A1 (no)
MX (1) MXPA06012758A (no)
NO (2) NO338736B1 (no)
PL (2) PL1742618T3 (no)
PT (2) PT1742618E (no)
RU (1) RU2006142706A (no)
SI (2) SI2275098T1 (no)
WO (1) WO2005105052A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4588791B2 (ja) * 2007-02-16 2010-12-01 あすか製薬株式会社 微粒子油性懸濁液を含む医薬組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117121A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. Method of increasing bile flow and decreasing lipid levels
JPH0616556A (ja) * 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
JPH07196483A (ja) 1993-11-25 1995-08-01 Taisho Pharmaceut Co Ltd 経口吸収性を改善した製剤組成物
JPH07165610A (ja) 1993-12-15 1995-06-27 Hiroshi Maeda 血圧制御剤
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FI100692B (fi) 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
CA2195623A1 (en) * 1994-07-22 1996-02-08 Rajeev D. Gokhale Self-emulsifying drug delivery system
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
FI101305B (fi) * 1996-03-18 1998-05-29 Map Medical Technologies Oy Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatse piini-johdannaiset ja niiden käyttö diagnostiikassa
CA2282411A1 (en) * 1997-02-27 1998-09-03 Nippon Shinyaku Co., Ltd. Fat emulsion for oral administration
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
WO2002056903A2 (en) * 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
FI20010115A0 (fi) * 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
ATE498408T1 (de) 2001-08-10 2011-03-15 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
JP2004045373A (ja) 2002-05-21 2004-02-12 Tanita Corp 電気化学式センサ
UA79797C2 (en) 2002-06-06 2007-07-25 Hormos Medical Corp Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations

Also Published As

Publication number Publication date
RU2006142706A (ru) 2008-06-20
JP2012149094A (ja) 2012-08-09
MXPA06012758A (es) 2007-01-16
USRE47316E1 (en) 2019-03-26
JP2014156495A (ja) 2014-08-28
PL1742618T3 (pl) 2013-01-31
JP5643255B2 (ja) 2014-12-17
PT2275098E (pt) 2012-08-29
DK2275098T3 (da) 2012-08-20
KR20070005715A (ko) 2007-01-10
PL2275098T3 (pl) 2012-12-31
NO338736B1 (no) 2016-10-17
CY1113284T1 (el) 2016-04-13
EP1742618B1 (en) 2012-08-22
WO2005105052A1 (en) 2005-11-10
JP5497983B2 (ja) 2014-05-21
CA2565134C (en) 2013-05-21
AU2005237274A1 (en) 2005-11-10
CA2565134A1 (en) 2005-11-10
JP5834111B2 (ja) 2015-12-16
CN1950071A (zh) 2007-04-18
AU2011202264B8 (en) 2012-04-05
EP1742618A1 (en) 2007-01-17
HK1151227A1 (en) 2012-01-27
KR101278934B1 (ko) 2013-06-26
AU2011202264A8 (en) 2012-04-05
EP2275098A1 (en) 2011-01-19
AU2011202264B2 (en) 2012-03-15
ES2392344T3 (es) 2012-12-07
NO20161206A1 (no) 2006-11-29
EP2275098B1 (en) 2012-07-25
BRPI0510465B8 (pt) 2021-05-25
PT1742618E (pt) 2012-10-11
NO343582B1 (no) 2019-04-08
JP2007536351A (ja) 2007-12-13
SI1742618T1 (sl) 2012-12-31
ES2391626T3 (es) 2012-11-28
DK1742618T3 (da) 2012-10-01
CY1113280T1 (el) 2016-04-13
SI2275098T1 (sl) 2012-12-31
BRPI0510465B1 (pt) 2019-08-27
AU2011202264A1 (en) 2011-06-09
BRPI0510465A (pt) 2007-11-06
AU2005237274B2 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
DE602005027540D1 (de) Feste formulierungen von ospemifen
RU2445312C2 (ru) ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
NO20082181L (no) Formuleringer av Fispemifen
CY1106150T1 (el) Μεθοδοι παρασκευης οπτικως καθαρης (r)- και (s)-διδεσμεθυλοσιβουτραμινης
LTC1713458I2 (lt) Ospemifeno bioaktyvumo padidinimo būdas
HRP20080052T3 (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
MX2010004232A (es) Compuesto de indolina de pirimidilo.
NO20064297L (no) Aminoalkoholforbindelse
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
EA200000700A2 (ru) НОВЫЕ β- КАРБОЛИНОВЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ
NI201200170A (es) Formulación farmacéutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg - coa reductasa e irbesartan
ES2573539T3 (es) Inhibidor de la cristalización y su uso en cápsulas de gelatina
NO20063662L (no) Benzimidazolderivater
NO20055601L (no) Farmasoytisk preparat i form av en hydrogel for transdermal administrasjon av aktive virkestoffer
SE0401655D0 (sv) New compounds
NO20065074L (no) Nye orale formuleringer av ospemifen.
UY28457A1 (es) Nueva composición
CR10506A (es) Derivados de acido fenilacetico
NO20076251L (no) Nye DHA derivater og deres anvendelse som medikamenter
NO20054319L (no) Neovaskulaseringspromoter
RU2446158C2 (ru) Замещенные изоиндолы в качестве ингибиторов васе и их применение
RU2007115741A (ru) Производные 4,6-диметил-2,3-дигидро-1н-пиразоло[4,3-с]пиридин-3-онов и эфиры 2,6-диметил-4-фенил-гидразиноникотиновых кислот в качестве промежуточных продуктов для их синтеза, обладающие антидепрессантной и анксиолитической активностью
ITMI20032020A1 (it) Nuovi agenti antifungini azolici con diminuita interazione con i citocromi metabolici
TH54911B (th) สูตรปลดปล่อยที่ควบคุม

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: QUATRX PHARMACEUTICALS, US

MM1K Lapsed by not paying the annual fees